|
Phase II Randomized Study of Lisinopril or
Carvedilol Phosphate Extended-Release in Reducing Cardiotoxicity in Women
With HER2-Positive Breast Cancer Receiving Adjuvant or Neoadjuvant
Trastuzumab (Lisinopril/Carvedilol
Phosphate/PLACEBO
Provided)
SCUSF-0806
(MBMC Contact:
Diana Christian 314-996-5888)
Click For Consent
(ONLY AVAILABLE AT MBMC and RURAL OUTREACHES)
A Phase III Randomized Trial of Metformin
vs Placebo in Early Stage Breast Cancer
(Metformin/Placebo
Provided)
NCIC MA.32
(MBMC Contact: Chris Sanders 314-996-5802)
Click
For Consent
(ONLY AVAILABLE AT MBMC
and RURAL OUTREACHES)
Phase III Randomized
Study of Standard Adjuvant Endocrine Therapy With Versus Without
Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive,
and HER2-Negative Breast Cancer (No Drugs Provided -
Click
Here To View Protocol Treatment Regimens)
SWOG S1007
(MBMC Contact: Henry
Robinson 314-996-5865)
Click
For Step 1 Consent
Click
For Step 2 Consent ***
Phase III Randomized Study of Adjuvant
Chemotherapy With Versus Without Trastuzumab in Women With Node-Positive or
High-Risk Node-Negative HER2-Low Invasive Breast Cancer
(Trastuzumab
Provided)
NSABP B-47
(MBMC Contact:
Chris Sanders 314-996-5802)
Click
For Consent
Phase III Randomized Study of Radiotherapy With
Versus Without Trastuzumab (Herceptin) in Women With HER2-Positive Ductal
Carcinoma In Situ Who Underwent Lumpectomy
(Tratuzumab Provided)
NSABP B-43 (MBMC Contact:
Chris Sanders 314-996-5802)
Click
For HER2 Testing Consent
Click
For Registration Consent
***Available through CTSU
← Previous
Next
→
|